Team:Arizona State/BSE
From 2013.igem.org
Line 16: | Line 16: | ||
We are utilizing the pOSIP plasmid to chromosomally integrate transformed genes into NEB 10 Beta cells and then remove antibiotic resistance genes to prevent horizontal gene transfer of LLO or any antibiotic resistance genes. We are also developing a pH-based gene switch to create a secondary safety mechanism so that LLO is only translated under acidic conditions and translation is repressed by neutral and basic conditions. | We are utilizing the pOSIP plasmid to chromosomally integrate transformed genes into NEB 10 Beta cells and then remove antibiotic resistance genes to prevent horizontal gene transfer of LLO or any antibiotic resistance genes. We are also developing a pH-based gene switch to create a secondary safety mechanism so that LLO is only translated under acidic conditions and translation is repressed by neutral and basic conditions. | ||
</p> | </p> | ||
- | + | <h3>pOSIP</h3> | |
+ | <p> | ||
+ | pOSIP is a system used to directly integrate genes into the genome of an organism. The ASU iGEM team plans to use this vector to deliver GFP and LLO directly into the genome to create a modular platform for cancer vaccine delivery, which can be altered simply by switching out a plasmid containing the cancer antigen of interest | ||
+ | </p> | ||
+ | <img src="#"> | ||
+ | <h3>LLO pH Switch</h3> | ||
</body> | </body> | ||
</html> | </html> |
Revision as of 22:20, 27 September 2013
Overview
We are utilizing the pOSIP plasmid to chromosomally integrate transformed genes into NEB 10 Beta cells and then remove antibiotic resistance genes to prevent horizontal gene transfer of LLO or any antibiotic resistance genes. We are also developing a pH-based gene switch to create a secondary safety mechanism so that LLO is only translated under acidic conditions and translation is repressed by neutral and basic conditions.
pOSIP
pOSIP is a system used to directly integrate genes into the genome of an organism. The ASU iGEM team plans to use this vector to deliver GFP and LLO directly into the genome to create a modular platform for cancer vaccine delivery, which can be altered simply by switching out a plasmid containing the cancer antigen of interest